Literature DB >> 25372777

Expression of the cAMP binding protein EPAC1 in thyroid tumors and growth regulation of thyroid cells and thyroid carcinoma cells by EPAC proteins.

M Broecker-Preuss1, J Baten1, S-Y Sheu-Grabellus2, R Görges3, A Bockisch3, K W Schmid2, D Führer1, K Mann1.   

Abstract

The thyrotropin receptor-cAMP pathway is central in growth regulation of thyroid cells and thyroid tumorigenesis, and it regulates expression of thyroid specific genes. Recently, 2 new protein kinase A-independent cAMP effectors named EPAC1 and 2 were described that activate additional intracellular pathways. The aim of our study was to investigate the role of EPAC proteins in growth regulation of thyroid cells and thyroid carcinomas. EPAC1 expression was investigated immunohistochemically in tissues of various thyroid tumors. Utilizing MTT assay, the effect of EPAC stimulation on proliferation in thyroid carcinoma cells and in non-transformed rat FRTL5 cells was investigated. The activation of intracellular signaling pathways was examined by RAP pull-down assay and Western blots. EPAC1 expression was strong in non-oxyphilic follicular thyroid adenomas and carcinomas and in follicular papillary thyroid carcinomas. It was moderate in oxyphilic follicular tumors and classical and tall cell papillary carcinomas. In contrast, EPAC1 expression was low in poorly differentiated carcinomas and very low in anaplastic carcinomas. Thyroid carcinoma cell lines showed no or very weak EPAC1 expression and exhibited no growth-promoting effect after EPAC stimulation. Non-transformed rat FRTL5 cells were growth-stimulated by an EPAC-specific cAMP-analogue and showed EPAC-dependent activation of RAP, ERK, and p70S6 kinase. EPAC1 expression and cellular response to EPAC activation in rat FRTL5 cells reflect cellular responses to cAMP and TSH stimulation in non-transformed thyroid cells. In undifferentiated thyroid carcinomas, loss of EPAC1 expression may be in accordance with the loss of thyroid-specific functions and the loss of responsiveness of the TSHR-cAMP pathway. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25372777     DOI: 10.1055/s-0034-1390484

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  4 in total

1.  Deletion of Rap1b, but not Rap1a or Epac1, Reduces Protein Kinase A-Mediated Thyroid Cancer.

Authors:  Danielle J Huk; Amruta Ashtekar; Alexa Magner; Krista La Perle; Lawrence S Kirschner
Journal:  Thyroid       Date:  2018-08-02       Impact factor: 6.568

Review 2.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 3.  Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP.

Authors:  Sarah A Smith; Andrew C Newby; Mark Bond
Journal:  Cells       Date:  2019-11-16       Impact factor: 7.666

4.  Identification of candidate aberrantly methylated and differentially expressed genes in Esophageal squamous cell carcinoma.

Authors:  Bao-Ai Han; Xiu-Ping Yang; Davood K Hosseini; Po Zhang; Ya Zhang; Jin-Tao Yu; Shan Chen; Fan Zhang; Tao Zhou; Hai-Ying Sun
Journal:  Sci Rep       Date:  2020-06-16       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.